Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the country. | The CEO voiced his concerns about Germany's new healthcare reform plan in a letter to Chancellor Friedrich Merz, according to reports.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Pharmaindustrie: Pfizer hinterfragt geplante Investitionen in Deutschland
Pharmabranche: Pfizer-Chef sagt Merz ab und stellt Investitionen in Frage
Pfizer alerta que investimentos na Alemanha estão em risco devido às políticas de preços
Standort Deutschland: Pfizer-Chef sagt Merz für Investitionsgipfel ab – und stellt Investitionen auf den Prüfstand - WELT
Pharmabranche: Pfizer-Chef sagt Merz ab und stellt Investitionen infrage
Pfizer-Chef sagt Merz ab und stellt Investitionen in Frage - WELT
Eli Lilly and Boehringer Ingelheim are cutting back on planned investments in Germany in response to a new government healthcare…
Even as the effort has met with fierce pushback from drugmakers, trade groups and opposition parties in the country’s own…
Following much opposition from drugmakers, Germany has scrapped its plan to install a program that would have reduced the price…
Amid efforts in Germany to retool the country’s drug spending, the U.S. | Amid efforts in Germany to retool the country’s drug…
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
Backlash is brewing against a sweeping overhaul of Germany’s health insurance system as Eli Lilly and Boehringer Ingelheim slash…
